Antiretroviral drug level monitoring: The next routine test in HIV management?

Current Opinion in Infectious Diseases

Volumn 12, Issue 6, 1999, Pages 593-595

  Hoetelmans, Richard M W ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY;

EID: 0033383172     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199912000-00010     Document Type: Short Survey

References (12)

1. 1 Stretcher BN, Pesce AJ, Murray JA, Hurtubise PE, Vine WH, Frame PT. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Therap Drug Monit 1991, 13:325-331.
2. 2 Hoetelmans RMW, Burger DM, Meenhorst PL, Beijnen JH. Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996, 30:314-327.
3. 3 Sommadossi JP, Valantin MA, Zhou XJ, Xie MY, Moore J, Calvez V, et al. Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine (ZDV) experienced HIV-infected patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1998 [Abstract 362].
4. 4 Hoetelmans RMW, van Heeswijk RPG, Meenhorst PL, Mulder JW, Scheele WA, Beijnen JH. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period. 12th World AIDS Conference, 1998, Geneva, Switzerland [Abstract 42261].
5. 5 Burger DM, Hoetelmans RMW, Hugen PWH, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Ther 1998, 3:215-220. One of the first manuscripts to describe the relationships between exposure in plasma and virological efficacy.
6. 6 Hoetelmans RMW, Reijers MHE, Weverling GJ, Jurriaans S, Lange JMA. The effect of plasma drug concentrations on HIV-1 clearance rate in antiretroviral naive patients during a quadruple drug combination regimen. AIDS 1998, 12:F111-115. This study shows the relationships between exposure to the P1 nelfinavir in plasma and early markers of antiviral activity, the initial HIV-1 RNA clearance rate.
7. 7 Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
8. 8 Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers DB, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999, 179:1116-1123.
9. 9 Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473-478.
10. 10 Gatti G, Di Bagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999, 13:2083-2089.
11. 11 Veldkamp AI, Hoetelmans RMW, Beijnen JH, on behalf of the INCAS study team. High exposure to nevirapine is associated with a higher initial HIV-1 clearance rate, a higher likelihood to reach undetectability and prolonged suppression of HIV-1 replication. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, October 1999 [Abstract 239].
12. 12 Joshi AS, Barrett JS, Fiske WD. Population pharmacokinetics of efavirenz in phase II studies and relationships with efficacy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 [Abstract 1201].